Healthcare / BiotechnologyStockholm
$30.05
-1.05 (-3.38%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 21%
FCF escenarios
weak_data · normalized FCF $-362.8M · quality 59.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
27/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$2.0B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-59.7%
↓Gross Margin
N/A
•Debt/Equity
0.02
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-11.4%
FCF CAGR
—
FCF margin
-112.6%
FCF / Net income
0.77x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $226.5M · net income $-332.9M · FCF $-255.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $226.5M | $226.5M | $44.7M | $71.5M | $326.1M |
| Net Income | $-332.9M | $-332.9M | $-429.4M | $-330.3M | $-42.5M |
| EBITDA | $-312.2M | $-312.2M | $-409.4M | $-320.2M | $-27.1M |
| EPS | -5.06 | -5.06 | -6.53 | -5.02 | -0.69 |
| Operating Margin | -155.1% | -155.1% | -1054.6% | -518.5% | -15.5% |
| Net Margin | -147.0% | -147.0% | -960.9% | -462.2% | -13.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 |
| Current Ratio | 5.32 | 5.32 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-255.0M | $-255.0M | $-390.5M | $-362.8M | $-53.6M |
| Returns | |||||
| ROE | -59.7% | -59.7% | -48.5% | -25.2% | -2.6% |
| Valuation | |||||
| P/B | 3.55 | 3.55 | 3.08 | 0.89 | 1.31 |
| Growth & Yield | |||||
| Revenue Growth | 406.9% | 406.9% | -37.5% | -78.1% | — |
| EPS Growth | 22.5% | 22.5% | -30.1% | -627.5% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-18.8%
Start / end P/E
n/dx → n/dx
EPS bridge
-6.53 → -5.06
Residual
-18.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.